Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study
Enrique Grande, Mustafa Sibai, Daniela Grases, Elena Andrada et autres
2 citationsCell Reports Medicine
Òscar Reig
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
141Publications signalées
1984Citations signalées
5Affiliations récentes
Institutions déclarées
Domaines associés
Prostate Cancer Treatment and ResearchCancer Immunotherapy and BiomarkersRenal cell carcinoma treatmentBladder and Urothelial Cancer TreatmentsRadiopharmaceutical Chemistry and Applications
Publications récentes
Non‐Cancer Causes of Death in Patients With Metastatic Hormone‐Sensitive Prostate Cancer: A Real‐World Analysis
Marta García de Herreros, Clara Rodrigo, Laura Ferrer-Mileo, Laia Fernández-Mañas et autres
0 citationsThe Prostate
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation
Capucine Baldini, Loïc Verlingue, Vincent Goldschmidt, Bernard Doger de Spéville et autres
11 citationsJournal of Clinical Oncology
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
Thomas Powles, Ariel Galapo Kann, Daniel Castellano, Marine Gross‐Goupil et autres
137 citationsNew England Journal of Medicine
Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18
Graham Cohen, Corlia Coetzee, Òscar Reig, Byoung Chul Cho et autres
7 citationsEuropean Journal of Cancer
Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study
Cristina Suárez, Òscar Reig, Rafael Morales‐Barrera, Ángel Rodríguez Sánchez et autres
1 citationClinical Genitourinary Cancer
Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression
Marta García de Herreros, Natàlia Jiménez, Joan Padrosa, Caterina Aversa et autres
4 citationsInternational Journal of Molecular Sciences
Corrigendum to “Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors” [Eur. Urol. Open Sci. 70 (2024) 86–90]
Marta García de Herreros, Natàlia Jiménez, Leonardo Rodríguez‐Carunchio, Mercedes Marín‐Aguilera et autres
0 citationsEuropean Urology Open Science
Sasanlimab as bladder-sparing maintenance treatment after neoadjuvant chemotherapy in patients with muscle invasive bladder cancer (MIBC): The phase 2, SASAN-SPARING trial.
Elena Sevillano, J. Martínez Pérez, Nuria Laínez Milagro, P. Gajate Borau et autres
1 citationJournal of Clinical Oncology
Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with previously untreated clear cell renal cell carcinoma (ccRCC): Results from an expansion cohort of the phase 1b STELLAR-002 study.
Jad Chahoud, Bradley A. McGregor, Òscar Reig, Pedro C. Barata et autres
1 citationJournal of Clinical Oncology
Phase 1/2 Duravelo-1 study: Preliminary results of nectin-4–targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer.
Patrizia Giannatempo, Matthew D. Galsky, I. Durán, Valentina Boni et autres
5 citationsJournal of Clinical Oncology
Corrigendum to “Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients” [Eur. Urol. Oncol. 7 (2024) 954–964]
Natàlia Jiménez, Marta García de Herreros, Òscar Reig, Mercedes Marín‐Aguilera et autres
0 citationsEuropean Urology Oncology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.